Fresenius Medical Care OKs €1.49 Dividend, Completes €1bn Buyback and Launches 5008X U.S. Rollout
At its Annual General Meeting, Fresenius Medical Care approved a €1.49 per share dividend and secured a new five-year share buyback authorization after a €1bn repurchase of 24.8m shares (8.5% of capital). The company posted 8% revenue growth, raised margin to 11.3%, and began U.S. rollout of FDA-approved 5008X CAREsystem.
1. AGM Decisions
Shareholders approved a €1.49 per share dividend for fiscal 2025 with 99.87% support and granted the Management Board a new five-year authorization to repurchase treasury shares. Approval votes of 84.67% and 97.42% ratified the Compensation Report and board actions, with 78.71% of share capital represented.
2. Financial Performance
Fresenius Medical Care achieved 8% organic revenue growth driven by all operating segments, lifted its operating margin to 11.3% from 7.9% over three years, and reduced net leverage to 2.5x from 3.4x in 2022. The company credited disciplined cost management and strategic investments for profitability improvements.
3. 5008X CAREsystem Launch
Following FDA approval of its hemodiafiltration-capable 5008X CAREsystem, Fresenius Medical Care introduced the device in select U.S. clinics and has initiated a full commercial rollout in 2026. With nearly 90% of U.S. in-center dialysis machines already sourced from the company, this upgrade marks the largest infrastructure refresh in its history.
4. Capital Allocation Framework
The initial €1 billion share buyback repurchased 24.8 million shares (8.5% of capital) in under one year, ahead of schedule. The firm maintains a dividend payout ratio of 30–40% of net income and will complement dividends with ongoing share repurchases to drive shareholder value.